Jean-Yves Douillard MD, PhDProfessor, Medical Oncology, University of Nantes, and Integrated Centers of Oncology ICO René Gauducheau Cancer, Nantes, France
Jean-Yves Douillard trained at the Medical School, University of Nantes, France and received its MD in 1979. He is Board certified in Medical Oncology, with a degree in experimental Oncology. He developed an interest in tumor immunology, obtained a fellowship from the Fogarty center (NIH, USA) and the French ministry of Health as Visiting Fellow Laboratory of Immuno-diagnosis (Ronald Herberman) at the National Cancer Institute, NIH, Bethesda Maryland USA. He became Assistant Professor of Medical Oncology in 1981 at the University of Nantes specializing in lung cancer, gastro-intestinal oncology and biotherapies. From 1986 to 1988, he went as a visiting scientist at the US FDA, Center for Biologics Evaluation and Research involved in monoclonal antibody therapy against colorectal cancer in a rat model. He got his PhD in 1993. He actively participated in clinical trials, in lung and GI tumors. In 2000, he became Professor of Medical Oncology.
He has published numerous articles in scientific journals (The Lancet, The New England Journal of Medicine, Journal of Clinical Oncology, The Lancet Oncology, British Journal of Cancer, Cancer Research, European Journal of Cancer, Annals of Oncology, Journal of Thoracic Oncology…) He was on the Editorial board of the Journal of Clinical Oncology, Clinical Colo-Rectal Cancer, Annals of Oncology and ESMO Open. He is a member of EORTC, ASCO, ESMO, IASLC, AACR. He was Head of Medical Oncology and then Director of Clinical and Translational Research at the Integrated Centers of Oncology, Nantes France until 06 2011. He was Board member at the French National Cancer Institute (Inca).
He served as Chair of the Gastro-Intestinal Tumor for the ESMO 2010 congress and Board member of GI Tumors for ESMO 2012. He joined the ESMO Executive Board as Chair of the ESMO Educational Committee 01 2012-12 2015. He was promoted Professor Emeritus in Oncology early 2016. He was nominated in May 2016 as ESMO Chief Medical Officer until July 2020. As of December 1, 2020, he is serving as a consultant in clinical trial research at the Integrated Centers of Oncology, Nantes, France.
Professor, Medical Oncology, University of Nantes (France); Director of Clinical and Translational Research, Rene Gauducheau Cancer Center Nantes (France)
University of Nantes, France, MD
University of Nantes, France, PhD
Resident, Centre Hospitalier Universitaire de Nantes, France
Fellow, French Ministry of Health and US National Institutes of Health John E. Fogarty
International Center for Advanced Study in the Health Sciences
Lung cancer, gastrointestinal cancer, monoclonal antibody therapy
Recent Contributions to PracticeUpdate:
- AACR 2021: Addition of Nivolumab to Neoadjuvant Chemotherapy Increases Pathologic Complete Response to Non-Small Cell Lung Cancer
- Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer
- First-Line Nivolumab + Ipilimumab Combined With Two Cycles of Chemotherapy in NSCLC
- 5-Year Outcomes With Nivolumab vs Docetaxel in Previously Treated NSCLC
- Durvalumab Therapy Following Chemoradiation vs Chemoradiation Alone in Patients With Stage III NSCLC
- First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
- Key Takeaways From ESMO: Updates on Small-Cell Lung Cancer
- Key Takeaways From ESMO: Adjuvant and Neoadjuvant Therapy for NSCLC
- Pembrolizumab vs Single-Agent Chemotherapy for Advanced Pretreated Malignant Pleural Mesothelioma
- KRASG 12C Inhibition With Sotorasib in Advanced Solid Tumors